KOL call: Idefirix for Kidney Transplantation

Our guest

Autolus
BioNTech
Cellectis
Evotec
Galapagos

Date: Nov 22th from 2:00pm CET

Join our chat with a European KOL to learn more about the use, adoption, and potential of Idefirix as a desensitization agent in patients undergoing kidney transplantation.

Kidney transplantation is not an option for candidates with high concentrations of donor specific IgG antibodies (DSA). Their only shot at a transplant may be to eliminate DSAs via desensitization. Imlifidase trials showed that, for the first time, a desensitization agent led to rapid and complete antibody depletion, regardless of their initial strength or number. Imlifidase has been approved in Europe (Idefirix).

Idefirix provides a dramatic improvement to desensitization, should ultimately become a mainstay in high-sensitized transplantation, and will not be easily replaced.

About Bryan, Garnier & Co

Bryan, Garnier & Co is a European growth investment bank that helps healthcare and technology companies become global champions. By combining extensive sector expertise with an entrepreneurial mindset, Bryan Garnier provides companies and their investors with independent growth strategic advice, and privileged access to buyers and capital in Europe, the US and Asia.

As a full-service investment bank, the firm offering includes private and public growth financing solutions, mergers and acquisitions (M&A) advisory, research insights, and institutional sales & execution. Founded in 1996, Bryan Garnier & Co is an independent partnership with around 200 employees located in major financial centres in Europe and the US.